TY - JOUR
T1 - Typhoid fever vaccines
T2 - Systematic review and meta-analysis of randomised controlled trials
AU - Fraser, Abigail
AU - Paul, Mical
AU - Goldberg, Elad
AU - Acosta, Camilo J.
AU - Leibovici, Leonard
N1 - Funding Information:
Funding : Work was supported by the Cochrane Infectious Diseases Group. The funding source had no involvement in the work undertaken.
PY - 2007/11/7
Y1 - 2007/11/7
N2 - We undertook a systematic review and meta-analysis of randomised controlled trials comparing a typhoid fever vaccine with any alternative typhoid fever vaccine or inactive agent. Trials evaluating killed whole-cell vaccines were excluded. The cumulative efficacy at 3 years for the Ty21a and the polysaccharide Vi vaccine were similar: 51% (95%CI 36%, 62%), and 55% (95%CI 30%, 70%), respectively. The cumulative efficacy of the Vi-rEPA vaccine at 3.8 years was higher, 89% (95%CI 76%, 97%), but this vaccine has not yet been licensed for use and was evaluated in only one trial. Adverse events were mild in nature and for most, not significantly more frequent in any of the vaccine groups when compared with placebo. Both the currently licensed Ty21a and Vi vaccine, are safe and efficacious for preventing typhoid fever. Neither vaccine is currently registered for administration to children below 2 years of age. Given the recent finding that typhoid fever also affects infants, development of a conjugate vaccine is warranted.
AB - We undertook a systematic review and meta-analysis of randomised controlled trials comparing a typhoid fever vaccine with any alternative typhoid fever vaccine or inactive agent. Trials evaluating killed whole-cell vaccines were excluded. The cumulative efficacy at 3 years for the Ty21a and the polysaccharide Vi vaccine were similar: 51% (95%CI 36%, 62%), and 55% (95%CI 30%, 70%), respectively. The cumulative efficacy of the Vi-rEPA vaccine at 3.8 years was higher, 89% (95%CI 76%, 97%), but this vaccine has not yet been licensed for use and was evaluated in only one trial. Adverse events were mild in nature and for most, not significantly more frequent in any of the vaccine groups when compared with placebo. Both the currently licensed Ty21a and Vi vaccine, are safe and efficacious for preventing typhoid fever. Neither vaccine is currently registered for administration to children below 2 years of age. Given the recent finding that typhoid fever also affects infants, development of a conjugate vaccine is warranted.
KW - Meta-analysis
KW - Salmonella typhi
KW - Systematic review
KW - Typhoid fever
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=35348819313&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2007.08.027
DO - 10.1016/j.vaccine.2007.08.027
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 17928109
AN - SCOPUS:35348819313
SN - 0264-410X
VL - 25
SP - 7848
EP - 7857
JO - Vaccine
JF - Vaccine
IS - 45
ER -
